BR9911779A - Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia - Google Patents

Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia

Info

Publication number
BR9911779A
BR9911779A BR9911779-7A BR9911779A BR9911779A BR 9911779 A BR9911779 A BR 9911779A BR 9911779 A BR9911779 A BR 9911779A BR 9911779 A BR9911779 A BR 9911779A
Authority
BR
Brazil
Prior art keywords
hyperglycemia
insulin resistance
benzofurans
treatment
benzothiophenes
Prior art date
Application number
BR9911779-7A
Other languages
English (en)
Inventor
Jay Edward Wrobel
Arlene Joan Dietrich
Madelene Miyoko Antane
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9911779A publication Critical patent/BR9911779A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Patente de Invenção: <B>"BENZOTIOFENOS, BENZOFURANOS E INDóIS úTEIS NO TRATAMENTO DE RESISTêNCIA à INSULINA E HIPERGLICEMIA"<D>. A presente invenção proporciona compostos da fórmula (I) em que Ar é (a), (b) ou (c) A, B, C, D, E, X, Y, Z1 e Z2 são conforme definido na descrição ou um sal farmaceuticamente aceitável dos mesmos, os quais são úteis no tratamento de distúrbios metabólicos relacionados à resistência à insulina ou hiperglicemia.
BR9911779-7A 1998-05-12 1999-05-10 Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia BR9911779A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12
PCT/US1999/010209 WO1999061435A1 (en) 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia

Publications (1)

Publication Number Publication Date
BR9911779A true BR9911779A (pt) 2001-02-06

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911779-7A BR9911779A (pt) 1998-05-12 1999-05-10 Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia

Country Status (22)

Country Link
EP (1) EP1077969A1 (pt)
JP (1) JP2002516321A (pt)
KR (1) KR20010043539A (pt)
CN (1) CN1308626A (pt)
AR (1) AR015294A1 (pt)
AU (1) AU756337B2 (pt)
BG (1) BG104918A (pt)
BR (1) BR9911779A (pt)
CA (1) CA2330620A1 (pt)
EA (1) EA200001175A1 (pt)
EE (1) EE200000653A (pt)
HR (1) HRP20000767A2 (pt)
HU (1) HUP0101792A3 (pt)
ID (1) ID26244A (pt)
IL (1) IL139132A0 (pt)
NO (1) NO20005677L (pt)
PL (1) PL344081A1 (pt)
SK (1) SK16992000A3 (pt)
TR (1) TR200003333T2 (pt)
TW (1) TW510900B (pt)
WO (1) WO1999061435A1 (pt)
ZA (1) ZA200005961B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
AU2001292518A1 (en) * 2000-09-26 2002-04-08 Biovitrum Ab Novel compounds
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
AR034373A1 (es) * 2001-06-07 2004-02-18 Wyeth Corp Inhibidores de ptpasa para mejorar el perfil de riesgo cardiovascular
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US20030008869A1 (en) * 2001-06-07 2003-01-09 Wyeth Combination of a PTPase inhibitor and a sulfonylurea agent
US20020198202A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent
US6797693B2 (en) 2001-06-07 2004-09-28 Wyeth Methods using PTPase inhibitors and insulin
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
US20030055058A1 (en) * 2001-06-07 2003-03-20 Wyeth Combination of a PTPase inhibitor and an ACE inhibitor
US6734197B2 (en) 2001-06-07 2004-05-11 Wyeth Combination therapy for type II diabetes or Syndrome X
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
EP1438044A1 (en) 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
WO2003048140A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
ITMI20022172A1 (it) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa Processo per la preparazione di 3-alchil-tiofeni-2, 5-disostituiti.
AU2003296323A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1723197A (zh) 2002-12-10 2006-01-18 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JPWO2004106542A1 (ja) 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
FR2862645B1 (fr) 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN105592846A (zh) 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法
CN107033122B (zh) * 2017-05-19 2019-06-14 南方医科大学 一种n-芳基-2-噻吩酰胺类衍生物及其制备方法和用途
US20210115397A1 (en) 2018-04-26 2021-04-22 Tokyo Institute Of Technology Method for promoting differentiation of pluripotent stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK123102B (da) * 1968-08-15 1972-05-15 Parke Davis & Co Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive benzo[b]thiopheneddikesyreforbindelser eller carboxylatsalte deraf.
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
JPH01135766A (ja) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd ビフェニル誘導体
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
CN1308626A (zh) 2001-08-15
ZA200005961B (en) 2001-10-24
PL344081A1 (en) 2001-09-24
NO20005677L (no) 2000-12-05
AU3893999A (en) 1999-12-13
EA200001175A1 (ru) 2001-06-25
ID26244A (id) 2000-12-07
BG104918A (bg) 2001-08-31
EE200000653A (et) 2002-04-15
HUP0101792A2 (hu) 2002-01-28
HUP0101792A3 (en) 2003-01-28
TW510900B (en) 2002-11-21
TR200003333T2 (tr) 2001-02-21
KR20010043539A (ko) 2001-05-25
AU756337B2 (en) 2003-01-09
NO20005677D0 (no) 2000-11-10
JP2002516321A (ja) 2002-06-04
AR015294A1 (es) 2001-04-18
HRP20000767A2 (en) 2001-10-31
EP1077969A1 (en) 2001-02-28
CA2330620A1 (en) 1999-12-02
WO1999061435A1 (en) 1999-12-02
IL139132A0 (en) 2001-11-25
SK16992000A3 (sk) 2001-04-09

Similar Documents

Publication Publication Date Title
BR9911779A (pt) Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
BR9915701A (pt) Composto, droga contendo um composto, e, uso de um composto
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
BR9916279A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos
BRPI0409914A (pt) ácidos carboxìlicos substituìdos
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
BR9917112A (pt) Compostos de imidazol e seu uso medicinal
RU94044454A (ru) Ингибитор аутоимунных заболеваний
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.